Stuttgart - Delayed Quote EUR

1B1.SG,0P0001M6G3,0 (1B1.SG)

3.2950

-0.0850

(-2.51%)

As of July 23 at 10:00:00 PM GMT+2. Market Open.

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024: Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed

GlobeNewswire 26 days ago

1B1.F
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.

This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further the continuation of the program and the development of new YKL-40 inhibitors. The Bio-dollar value of the agre

GlobeNewswire 6 months ago

1B1.F
Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs

WARSAW, Poland & DURHAM, N.C., July 31, 2024--Molecure S.A. (‘Molecure’, SWE Ticker: MOC) and Avicenna Biosciences, Inc. announced today that they have entered into a strategic research collaboration to facilitate the discovery and development of novel small molecule drugs targeting ubiquitin-specific protease 7 (USP7), a deubiquitinase relevant in a number of tumors. The collaboration will combine the extensive expertise of Molecure related to drug discovery and biology of USP7 with Avicenna’s

Business Wire 8 months ago

MOC.WA
Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway

OATD-01 is a first-in-class chitotriosidase 1 (CHIT1) inhibitor with the potential to modify the course of disease in sarcoidosis and other interstitial lung diseases.Obtaining regulatory approvals in Denmark, France, Greece, Germany, and Norway enables the conduct of the Phase II clinical trial of OATD-01 in these countries.First administration of OATD-01 in the European Union and Norway is planned for the third quarter of this year.Previously, Molecure received clinical trial approvals from th

GlobeNewswire 10 months ago

1B1.F

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

1B1.SG,0P0001M6G3,0 (1B1.SG)

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.

Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs

Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway